Alto Neuroscience Inc
ANRO19.690USD
-0.350-1.75%
Close 12/23, 16:00（ET）Quotes delayed by 15 min
534.94MMarket Cap
LossP/E TTM
More Details of Alto Neuroscience Inc Company
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
Alto Neuroscience Inc Info
Ticker SymbolANRO
Company nameAlto Neuroscience Inc
IPO dateFeb 02, 2024
CEOEtkin (Amit)
Number of employees76
Security typeOrdinary Share
Fiscal year-endFeb 02
Address650 Castro Street, Suite 450
CityMOUNTAIN VIEW
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code94041
Phone17732555012
Websitehttps://www.altoneuroscience.com/
Ticker SymbolANRO
IPO dateFeb 02, 2024
CEOEtkin (Amit)
Company Executives of Alto Neuroscience Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Ms. Gwill York
Ms. Gwill York
Independent Director
Independent Director
--
--
Mr. Nicholas (Nick) Smith
Mr. Nicholas (Nick) Smith
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Hanley
Mr. Michael Hanley
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Amit Etkin, M.D., Ph.D.
Dr. Amit Etkin, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.21M
--
Mr. Christopher Nixon (Chris) Cox
Mr. Christopher Nixon (Chris) Cox
Independent Director
Independent Director
715.65K
--
Mr. Adam Savitz, M.D., Ph.D.
Mr. Adam Savitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.85K
+216.53%
Dr. Ramiro (Raymond) Sanchez, M.D.
Dr. Ramiro (Raymond) Sanchez, M.D.
Independent Director
Independent Director
--
--
Dr. Husseini Manji, M.D.
Dr. Husseini Manji, M.D.
Director
Director
--
--
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Wave Global, LP
11.94%
Perceptive Advisors LLC
6.40%
Commodore Capital LP
5.32%
Armistice Capital LLC
5.27%
Point72 Asset Management, L.P.
4.29%
Other
66.78%
Shareholders
Shareholders
Proportion
Alpha Wave Global, LP
11.94%
Perceptive Advisors LLC
6.40%
Commodore Capital LP
5.32%
Armistice Capital LLC
5.27%
Point72 Asset Management, L.P.
4.29%
Other
66.78%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.92%
Investment Advisor/Hedge Fund
16.28%
Venture Capital
12.08%
Investment Advisor
10.48%
Private Equity
7.21%
Individual Investor
6.52%
Research Firm
0.45%
Sovereign Wealth Fund
0.25%
Family Office
0.20%
Other
27.62%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
193
20.44M
83.26%
+3.62M
2025Q3
188
16.82M
94.96%
-538.33K
2025Q2
179
17.35M
105.59%
-3.64M
2025Q1
164
21.00M
107.26%
-8.04M
2024Q4
146
22.58M
87.81%
-728.68K
2024Q3
123
23.05M
67.05%
+5.32M
2024Q2
92
17.73M
59.45%
+1.75M
2024Q1
62
15.98M
28.13%
+8.42M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Wave Global, LP
3.71M
13.69%
--
--
Jun 30, 2025
Armistice Capital LLC
1.62M
6%
+24.00K
+1.50%
Jun 30, 2025
Point72 Asset Management, L.P.
1.33M
4.91%
+89.70K
+7.23%
Jun 30, 2025
Etkin (Amit)
1.21M
4.45%
--
--
Mar 17, 2025
Franklin Advisers, Inc.
1.16M
4.29%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.08M
4.01%
-133.94K
-10.99%
Jun 30, 2025
Vestal Point Capital, LP
950.00K
3.51%
+35.00K
+3.83%
Jun 30, 2025
Marshall Wace LLP
937.41K
3.46%
+84.42K
+9.90%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
7.21%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Schwab U.S. Small-Cap ETF
0%
ALPS Medical Breakthroughs ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
Schwab U.S. Broad Market ETF
0%
View more
AdvisorShares Psychedelics ETF
Proportion7.21%
iShares Micro-Cap ETF
Proportion0.06%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alto Neuroscience Inc?
The top five shareholders of Alto Neuroscience Inc are:
Alpha Wave Global, LP holds 3.71M shares, accounting for 13.69% of the total shares.
Armistice Capital LLC holds 1.62M shares, accounting for 6.00% of the total shares.
Point72 Asset Management, L.P. holds 1.33M shares, accounting for 4.91% of the total shares.
Etkin (Amit) holds 1.21M shares, accounting for 4.45% of the total shares.
Franklin Advisers, Inc. holds 1.16M shares, accounting for 4.29% of the total shares.
Alpha Wave Global, LP holds 3.71M shares, accounting for 13.69% of the total shares.
Armistice Capital LLC holds 1.62M shares, accounting for 6.00% of the total shares.
Point72 Asset Management, L.P. holds 1.33M shares, accounting for 4.91% of the total shares.
Etkin (Amit) holds 1.21M shares, accounting for 4.45% of the total shares.
Franklin Advisers, Inc. holds 1.16M shares, accounting for 4.29% of the total shares.
What are the top three shareholder types of Alto Neuroscience Inc?
The top three shareholder types of Alto Neuroscience Inc are:
Alpha Wave Global, LP
Perceptive Advisors LLC
Commodore Capital LP
Alpha Wave Global, LP
Perceptive Advisors LLC
Commodore Capital LP
How many institutions hold shares of Alto Neuroscience Inc (ANRO)?
As of 2025Q4, 193 institutions hold shares of Alto Neuroscience Inc, with a combined market value of approximately 20.44M, accounting for 83.26% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -11.69%.
What is the biggest source of revenue for Alto Neuroscience Inc?
In --, the -- business generated the highest revenue for Alto Neuroscience Inc, amounting to -- and accounting for --% of total revenue.
